XML 82 R69.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2014
Jan. 01, 2018
Revenue          
Accumulated Deficit $ (962,438) $ (812,517)      
Deferred Revenue 1,586 2,813      
Accounts receivable 3,162 1,880      
Revenue recognized from contract liabilities 1,900        
Revenues 9,538 12,743 $ 6,786    
ASU 2014-09          
Revenue          
Accumulated Deficit         $ (1,300)
Deferred Revenue         (800)
Accounts receivable         $ 500
Product Development and Licensing Agreements          
Revenue          
Revenues 3,341 3,153 2,174    
Contracts and Grants          
Revenue          
Revenues 6,197 9,590 4,612    
Bristol-Myers Squibb Company | Product Development and Licensing Agreements          
Revenue          
Deferred Revenue       $ 5,000  
Reimbursement of external costs (as percent)       50.00%  
Revenues 3,300 2,800 2,100    
IAVI & Frontier | Contracts and Grants          
Revenue          
Revenues 3,000 6,600      
Rockefeller | Contracts and Grants          
Revenue          
Revenues $ 2,600 $ 2,200 $ 2,700